Background: There is controversy about whether therapy with inhaled corticosteroids (ICSs) modifies the natural history of COPD, characterized by an accelerated decline in FEV 1. Methods: The Inhaled ...
NEW ORLEANS — In a post hoc analysis of the LIBERTY ASTHMA VENTURE study, treatment with dupilumab resulted in reduced severe asthma exacerbations in patients with oral corticosteroid-dependent severe ...
The GOLD 2024/2025 reports underscore the importance of spirometry in confirming a COPD diagnosis, with a post-bronchodilator ...
Forest Laboratories and Glenmark Pharmaceuticals announced top-line results from a Phase 2b dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). This ...
Please provide your email address to receive an email when new articles are posted on . Patients with oral corticosteroid-dependent, severe eosinophilic asthma treated with benralizumab achieved ...
The guideline-recommended FEV1:FVC value of less than 0.70 is the optimal cutoff for the diagnosis of clinically significant chronic obstructive pulmonary disease (COPD), researchers say. The study, ...
Pharmacologic class: Selective phosphodiesterase 4 (PDE4) inhibitor. Active ingredient: Roflumilast 500 μg; tabs. Indication: To reduce risk of chronic obstructive pulmonary disease (COPD) ...
The underdiagnosed and poor management of COPD exacerbations represents a missed opportunity to prevent patient deterioration through proactive treatment approaches. Chronic obstructive pulmonary ...
Investigators found that the ratio of lymphocytes to high-density lipoprotein (HDL) performed better in predicting pulmonary function than the neutrophil-lymphocyte ratio and the platelet-lymphocyte ...
NEW YORK--(BUSINESS WIRE)--Nycomed and Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE: FRX), today announced that they have entered into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback